Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,870 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neurocognitive Dysfunction Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Wake Forest Alzheimer's Disease Clinical Core

NCT03140865
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 11:04 PM EDT
Not listed No phase listed Observational

Microbiome Composition and Function Contributes to Cognitive Impairment and Neuroinflammation in Parkinson's Disease

NCT05419453
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
California State University, San Bernardino
Other
Eligibility
55 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 23, 2026, 11:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 23, 2026, 11:04 PM EDT
Completed Not applicable Interventional

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

NCT06595030
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Active Lighting Intervention, Control Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Menands, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 11:04 PM EDT
Recruiting Not applicable Interventional

BID LTM Digital Intervention in Aging

NCT06916221
View directory record Official record
Conditions
Long-Term Memory, Inhibitory Control, Mild Cognitive Impairment
Interventions
Long Term Memory, Worder
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 11:04 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
KarXT, KarX-EC, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Long Beach, California • Redlands, California • Basalt, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 11:04 PM EDT
Terminated Phase 3 Interventional Results available

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

NCT02284906
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 23, 2026, 11:04 PM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 23, 2026, 11:04 PM EDT
Not listed Not applicable Interventional

Lifestyle Intervention Program for Cognitive Impairment

NCT02741804
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
BBH-1001 Brain Health Supplement, Lifestyle Intervention, Brain Health Placebo
Dietary Supplement · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
55 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 23, 2026, 11:04 PM EDT
Recruiting Not applicable Interventional

Preventing Medication Mismanagement in People Living With Dementia

NCT07600684
View directory record Official record
Conditions
Dementia
Interventions
HiDO HomeCareSystem
Device
Lead sponsor
HiDO Technologies
Industry
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Folsom, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 11:04 PM EDT
Completed Not applicable Interventional

Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION)

NCT05217849
View directory record Official record
Conditions
Mild Cognitive Impairment, Subjective Memory Decline
Interventions
Tai Chi, Preventing Loss of Independence through Exercise (PLIE), Health and Wellness Education
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 11:04 PM EDT
Completed No phase listed Observational Results available

Screening and Interventions in an Acute Care Setting

NCT00545155
View directory record Official record
Conditions
Depression, Medication Administered in Error, Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
65 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 23, 2026, 11:04 PM EDT
Terminated Phase 2 Interventional Results available

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 23, 2026, 11:04 PM EDT
Active, not recruiting Phase 2 Interventional

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

NCT06069843
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
IV Ketamine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 23, 2026, 11:04 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

NCT04141150
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
Interventions
[18F]APN-1607
Drug
Lead sponsor
APRINOIA Therapeutics, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Mount Arlington, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 11:04 PM EDT
Completed Phase 2 Interventional

Tricaprilin In Age-Associated Memory Impairment

NCT00355550
View directory record Official record
Conditions
Age-Associated Memory Impairment
Interventions
Tricaprilin, Placebo
Drug · Other
Lead sponsor
Cerecin
Industry
Eligibility
50 Years to 85 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Brooksville, Florida • DeLand, Florida • Naples, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 23, 2026, 11:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cognitive Engagement and Aging Mind

NCT05924490
View directory record Official record
Conditions
Age-related Cognitive Decline
Interventions
Real-time strategy-based videogame training, Semantic Knowledge training
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
50 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 23, 2026, 11:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multicomponent Program for Addressing Cognition in Rural Communities

NCT07018830
View directory record Official record
Conditions
Cognitive Decline
Interventions
Behavioral Treatment
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 23, 2026, 11:04 PM EDT
Not listed Phase 2 Interventional

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease

NCT01811381
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Curcumin, aerobic yoga, non aerobic yoga, Placebo
Drug · Behavioral · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 23, 2026, 11:04 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessing Cognitive Decline at Home

NCT06704971
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Dementia Alzheimers, Dementia, Memory Impairment, NPS
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 11:04 PM EDT
Recruiting No phase listed Observational

Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

NCT06058234
View directory record Official record
Conditions
Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Drug
Lead sponsor
Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Federal
Eligibility
Not listed
Enrollment
8,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 11:04 PM EDT
Completed Not applicable Interventional

Attention Training for Learning Enhancement and Resilience Trial

NCT02416401
View directory record Official record
Conditions
Age-related Cognitive Decline
Interventions
Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
65 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 23, 2026, 11:04 PM EDT
Not yet recruiting No phase listed Observational

Navigating the Clinical Research Process for Mild Cognitive Impairment

NCT06207903
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 23, 2026, 11:04 PM EDT
Terminated Not applicable Interventional

A Virtually Delivered Exercise Intervention To Mitigate Cognitive Deficits From Radiotherapy In AYAs With Brain Tumors

NCT05554159
View directory record Official record
Conditions
Brain Tumor, Brain Cancer
Interventions
Standard Fitbit Program, Virtual Exercise Program
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 23, 2026, 11:04 PM EDT